» Articles » PMID: 31504452

How to Diagnose Heart Failure with Preserved Ejection Fraction: the HFA-PEFF Diagnostic Algorithm: a Consensus Recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)

Abstract

Making a firm diagnosis of chronic heart failure with preserved ejection fraction (HFpEF) remains a challenge. We recommend a new stepwise diagnostic process, the 'HFA-PEFF diagnostic algorithm'. Step 1 (P=Pre-test assessment) is typically performed in the ambulatory setting and includes assessment for HF symptoms and signs, typical clinical demographics (obesity, hypertension, diabetes mellitus, elderly, atrial fibrillation), and diagnostic laboratory tests, electrocardiogram, and echocardiography. In the absence of overt non-cardiac causes of breathlessness, HFpEF can be suspected if there is a normal left ventricular ejection fraction, no significant heart valve disease or cardiac ischaemia, and at least one typical risk factor. Elevated natriuretic peptides support, but normal levels do not exclude a diagnosis of HFpEF. The second step (E: Echocardiography and Natriuretic Peptide Score) requires comprehensive echocardiography and is typically performed by a cardiologist. Measures include mitral annular early diastolic velocity (e'), left ventricular (LV) filling pressure estimated using E/e', left atrial volume index, LV mass index, LV relative wall thickness, tricuspid regurgitation velocity, LV global longitudinal systolic strain, and serum natriuretic peptide levels. Major (2 points) and Minor (1 point) criteria were defined from these measures. A score ≥5 points implies definite HFpEF; ≤1 point makes HFpEF unlikely. An intermediate score (2-4 points) implies diagnostic uncertainty, in which case Step 3 (F1: Functional testing) is recommended with echocardiographic or invasive haemodynamic exercise stress tests. Step 4 (F2: Final aetiology) is recommended to establish a possible specific cause of HFpEF or alternative explanations. Further research is needed for a better classification of HFpEF.

Citing Articles

Metabolomic Panel for the Diagnosis of Heart Failure with Preserved Ejection Fraction.

Kozhevnikova M, Kakotkina A, Korobkova E, Kuznetsov I, Shestakova K, Moskaleva N Int J Mol Sci. 2025; 26(5).

PMID: 40076723 PMC: 11900465. DOI: 10.3390/ijms26052102.


Revolutionising Cardio-Oncology Care with Precision Genomics.

Chong J, Chuah C, Lee C Int J Mol Sci. 2025; 26(5).

PMID: 40076674 PMC: 11900203. DOI: 10.3390/ijms26052052.


Prognostic Value of B-Type Natriuretic Peptide Level in Patients With Heart Failure With a Higher Left Ventricular Ejection Fraction.

Ohte N, Kikuchi S, Iwahashi N, Kinugasa Y, Dohi K, Takase H Circ Rep. 2025; 7(3):191-197.

PMID: 40066216 PMC: 11890284. DOI: 10.1253/circrep.CR-24-0172.


Heart failure with preserved ejection fraction and metabolic dysfunction-associated steatotic liver disease: Twin challenges, one metabolic solution.

Lian L, Huang C, Chen Q, Zhou X World J Cardiol. 2025; 17(2):103845.

PMID: 40061276 PMC: 11886398. DOI: 10.4330/wjc.v17.i2.103845.


Integrating pre-ablation and post-ablation B-type natriuretic peptide to identify high-risk population for long-term adverse events and arrhythmic recurrence in persistent atrial fibrillation.

Ishiguchi H, Yoshiga Y, Fukuda M, Fujii S, Hisaoka M, Hashimoto S Open Heart. 2025; 12(1).

PMID: 40021208 PMC: 11873341. DOI: 10.1136/openhrt-2025-003251.